Evidence map›Paper›PMID 40687785›Full record

ArticleiScience2025

Differential substrate degradation by super-degron: EGFP in wild-type mouse cells, PD-1 requires CRBN humanization.

Chie Naruse, Ojiro Ishibashi, Masatoshi Ohgushi, Hirohiko Imai, Tomoko Matsuzaki, Xuchi Pan, Tatsuhiko Miyazaki, Yuka Shidahara, Yu Shirakawa, Fumihiro Sugiyama and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chie NaruseInstitute of Laboratory Animals, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.
Ojiro IshibashiInstitute of Laboratory Animals, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.
Masatoshi OhgushiLaboratory of Developmental Systems, Department of Biosystems Science, Institute for Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
Hirohiko ImaiDepartment of Informatics, Graduate School of informatics, Kyoto University, Kyoto 606-8501, Japan.
Tomoko MatsuzakiInstitute of Laboratory Animals, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.
Xuchi PanInstitute of Laboratory Animals, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.
Tatsuhiko MiyazakiDepartment of Pathology, Gifu University Hospital, Gifu 501-1194, Japan.
Yuka ShidaharaBioscience Business Division, KAC Co., Ltd. Ritto, Shiga 520-3001, Japan.
Yu ShirakawaBioscience Business Division, KAC Co., Ltd. Ritto, Shiga 520-3001, Japan.
Fumihiro SugiyamaLaborarory Animal Resource Center, Transborder Medical Research Center, Institute of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan.
Masahide AsanoInstitute of Laboratory Animals, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein knockdown using a zinc finger degron tag and thalidomide analogs was previously considered ineffective in mouse cells. However, using EGFP as an indicator, we found that a super-degron tag (SD) enables degradation in mouse cells when combined with iberdomide or mezigdomide. While SD-tagged EGFP was degraded in wild-type mouse cells, SD-tagged PD-1 required human-type CEREBLON (CRBN

Indexed as

Biological sciencesImmunologyNatural sciences

Identifiers

PMID40687785
PMCPMC12274739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.